Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BioXcel Therapeutics Inc

Current price
3.17 USD -0.35 USD (-9.94%)
Last closed 3.57 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 113 870 808 USD
Yield for 12 month -81.37 %
21.11.2021 - 28.11.2021

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. Address: 555 Long Wharf Drive, New Haven, CT, United States, 06511


WallStreet Target Price

14 USD

P/E ratio

Dividend Yield

Current Year

+375 000 USD

Last Year

Current Quarter

+341 000 USD

Last Quarter

+457 000 USD

Current Year

+355 000 USD

Last Year

Current Quarter

-171 000 USD

Last Quarter

+431 000 USD

Key Figures BTAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -200 316 992 USD
Operating Margin TTM -12942.52 %
PE Ratio
Return On Assets TTM -72.64 %
PEG Ratio
Return On Equity TTM -489.95 %
Wall Street Target Price 14 USD
Revenue TTM 1 242 000 USD
Book Value -1.39 USD
Revenue Per Share TTM 0.043 USD
Dividend Share
Quarterly Revenue Growth YOY 148.9 %
Dividend Yield
Gross Profit TTM 355 000 USD
Earnings Share -7.36 USD
Diluted Eps TTM -7.36 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BTAI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BTAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BTAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 99.6976
Price Sales TTM 91.6834
Enterprise Value EBITDA -0.6238
Price Book MRQ 3.9656

Financials BTAI

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BTAI

For 52 weeks

2.23 USD 34.13 USD
50 Day MA 3.48 USD
Shares Short Prior Month 5 810 180
200 Day MA 13.01 USD
Short Ratio 0.78
Shares Short 5 076 946
Short Percent 67.45 %